|Articles|September 2, 2014

"Evidence" Trail Elusive - Video

Nancy Dreyer, PhD, MPH, FISPe, discusses the importance of non-interventional studies.

Newsletter

Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.

Related Content

Breaking the Efficacy Ceiling in IBD and Beyond

ByMichael Christel,Kori Wallace, MD, PhD

August 11th 2026

ACT Brief: Substance Versus Branding in Biotech Support, Site-Level Execution Gaps and Point-of-Care Data, and KCNT1-Targeted Pediatric Epilepsy Program

ByAndy Studna, Senior Editor

August 11th 2026

Why Clinical Trial Modernization Fails Without Point-of-Care Data: Q&A with Richard Graham, PhD, TruTechnologies

ByRichard Graham, PhD

August 10th 2026

How to Tell Substance from Branding in Biotech's Support Ecosystem

ByStella K. Vnook, PhD

August 10th 2026

ACT Brief: Lean Development Through Fractional Teams and Partners, FDA Expedited IND Pilot for Phase I Acceleration, and Tudriqev Accelerated Approval for Anti-PD-1-Refractory Melanoma

ByAndy Studna, Senior Editor

August 10th 2026

Trending on Applied Clinical Trials Online

Why Clinical Trial Modernization Fails Without Point-of-Care Data: Q&A with Richard Graham, PhD, TruTechnologies

FDA Makes Case for Overhauling Early Clinical Development to Reclaim US Leadership

ACT Brief: Lean Development Through Fractional Teams and Partners, FDA Expedited IND Pilot for Phase I Acceleration, and Tudriqev Accelerated Approval for Anti-PD-1-Refractory Melanoma

ACT Brief: Commercial Strategy Shaping Early Clinical Development, Real-Time Trials Require Operational Infrastructure, and AI Site Engagement Gap

How to Tell Substance from Branding in Biotech's Support Ecosystem